Julie Janes

2.2k total citations · 1 hit paper
19 papers, 1.3k citations indexed

About

Julie Janes is a scholar working on Biotechnology, Cancer Research and Oncology. According to data from OpenAlex, Julie Janes has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Biotechnology, 7 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Julie Janes's work include Cancer Research and Treatments (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Amino Acid Enzymes and Metabolism (3 papers). Julie Janes is often cited by papers focused on Cancer Research and Treatments (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Amino Acid Enzymes and Metabolism (3 papers). Julie Janes collaborates with scholars based in United States. Julie Janes's co-authors include Francesco Parlati, Mirna L.M. Rodriguez, Mark K. Bennett, Evan R. Lewis, Frances Zhao, Susan D. Demo, Peter J. Shwonek, Jinfu Yang, Taotao Wang and Andrew L. MacKinnon and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Neuroscience and Blood.

In The Last Decade

Julie Janes

16 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

2014 797 citations Matt I. Gross, Susan D. Demo et al. Molecular Cancer Therapeutics profile →

Peers

Countries citing papers authored by Julie Janes

Since Specialization

Citations

This map shows the geographic impact of Julie Janes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Janes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Janes more than expected).

Fields of papers citing papers by Julie Janes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Janes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Janes. The network helps show where Julie Janes may publish in the future.

Co-authorship network of co-authors of Julie Janes

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Janes. A scholar is included among the top collaborators of Julie Janes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Janes. Julie Janes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response 2025 ·Oncotarget ·Kyle R. Cron, Ping Fang, Oanh Pham, Julie Janes, (unknown), William Lu, Jianzhong Zhu, (unknown), (unknown), (unknown), Anastasia A. Makarova, Andrea Iannello, Jean H. Chan, Justin Skoble, (unknown), Chris S. Rae, Christopher D. Thanos, Akshata R. Udyavar	0
2	Abstract 576: ACTM-838, a novel immunotherapy that enriches in solid tumors after IV dosing and comprehensively reverses the immunosuppressive TME to promote durable anti-tumor immunity 2023 ·Cancer Research ·Ping Fang, Kyle R. Cron, Oanh Pham, Julie Janes, (unknown), Fauna Yarza, (unknown), Christopher D. Thanos, Chan C. Whiting, Akshata R. Udyavar	1
3	Abstract 552: Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response 2016 ·Cancer Research ·Melissa Works, Mark K. Bennett, (unknown), Ethan Emberley, Tony Chieh‐Ting Huang, Julie Janes, Weiqun Li, (unknown), Gisele Marguier, Silinda Neou, Alison Pan, Francesco Parlati, Mirna L.M. Rodriguez, Susanne Steggerda, Tracy Wang, Jing Zhang, Winter Zhang, Matthew Gross	10
4	Abstract 2329: Glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation 2016 ·Cancer Research ·Matt Gross, Jason Chen, (unknown), Julie Janes, Robert D. Leone, (unknown), Francesco Parlati, (unknown), Peter J. Shwonek, Jonathan D. Powell	16
5	Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma 2015 ·Blood ·Andrew L. MacKinnon, Mark K. Bennett, Matt Gross, Julie Janes, Weiqin Li, (unknown), Tracy Wang, Winter Zhang, Francesco Parlati	4
6	Abstract A195: CB-1158 inhibits the immuno-oncology target arginase and causes an immune mediated anti-tumor response 2015 ·Molecular Cancer Therapeutics ·Matthew Gross, Jason Chen, Ethan Emberley, Julie Janes, Weiqun Li, (unknown), Alison Pan, Francesco Parlati, Mirna L.M. Rodriguez, Susanne Steggerda, Tracy Wang, Melissa Works, Jing Zhang, Winter Zhang, Mark K. Bennett	4
7	Abstract 4711: CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity 2015 ·Cancer Research ·Mirna L.M. Rodriguez, Winter Zhang, Mark K. Bennett, Ethan Emberley, (unknown), Julie Janes, Andrew L. MacKinnon, Alison Pan, Susanne Steggerda, Melissa Works, Francesco Parlati	4
8	Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer breakdown → 2014 ·Molecular Cancer Therapeutics ·Matt I. Gross, Susan D. Demo, Jennifer B. Dennison, Lijing Chen, Tania Chernov-Rogan, Bindu Goyal, Julie Janes, Guy J. Laidig, Evan R. Lewis, Jun Li, Andrew L. MacKinnon, Francesco Parlati, Mirna L.M. Rodriguez, Peter J. Shwonek, Eric B. Sjogren, Timothy F. Stanton, Taotao Wang, Jinfu Yang, Frances Zhao, Mark K. Bennett	797
9	Comparison of AMG 416 and cinacalcet in rodent models of uremia 2014 ·BMC Nephrology ·Sarah Walter, Amos Baruch, Shawn T. Alexander, Julie Janes, Eiketsu Sho, (unknown), (unknown), Derek Maclean, Dirk B. Mendel, Felix Karim, Randolph M. Johnson	20
10	Glutaminase Inhibitor CB-839 Synergizes with Pomalidomide in Preclinical Multiple Myeloma Models 2014 ·Blood ·Francesco Parlati, (unknown), Julie Janes, Evan R. Lewis, (unknown), Mirna L.M. Rodriguez, Peter J. Shwonek, Mark K. Bennett	7
11	Abstract 1416: CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies 2014 ·Cancer Research ·Francesco Parlati, Susan D. Demo, Matthew Gross, Julie Janes, Evan R. Lewis, (unknown), Mirna L.M. Rodriguez, Peter J. Shwonek, Taotao Wang, Jinfu Yang, Dong Zhang, Frances Zhao, Mark K. Bennett	12
12	Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients 2013 ·Journal of Pharmacology and Experimental Therapeutics ·Sarah Walter, Amos Baruch, (unknown), James Tomlinson, Shawn T. Alexander, Julie Janes, (unknown), (unknown), Derek Maclean, Gregory Bell, Dirk B. Mendel, Randolph M. Johnson, Felix Karim	84
13	Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances 2013 ·Blood ·Francesco Parlati, (unknown), Susan D. Demo, Julie Janes, Matt Gross, Evan R. Lewis, (unknown), Mirna L.M. Rodriguez, Jinfu Yang, Frances Zhao, Mark K. Bennett	21
14	Abstract 1877: Anti-tumor activity of novel, potent, selective and orally-bioavailable glutaminase inhibitors. 2013 ·Cancer Research ·Francesco Parlati, Tania Chernov-Rogan, Susan D. Demo, Matthew Gross, Julie Janes, Raja Kawas, Evan R. Lewis, Hector Rodriguez‐Villalobos, Mirna L.M. Rodriguez, Jinfu Yang, Frances Zhao, Adam Richardson, Mark K. Bennett	0
15	A shed form of LDL receptor–related protein–1 regulates peripheral nerve injury and neuropathic pain in rodents 2008 ·Journal of Clinical Investigation ·Alban Gaultier, Sanja Arandjelovic, Xiaoqing Li, Julie Janes, (unknown), (unknown), (unknown), Robert R. Myers, Steven L. Gonias, W. Marie Campana	53
16	Cytokine regulation of MMP-9 in peripheral glia: Implications for pathological processes and pain in injured nerve 2007 ·Brain Behavior and Immunity ·Sharmila Chattopadhyay, Robert R. Myers, Julie Janes, Veronica I. Shubayev	117
17	The Low-Density Lipoprotein Receptor-Related Protein Is a Pro-Survival Receptor in Schwann Cells: Possible Implications in Peripheral Nerve Injury 2006 ·Journal of Neuroscience ·W. Marie Campana, Xiaoqing Li, (unknown), Julie Janes, Alban Gaultier, Steven L. Gonias	91
18	Omega-3 polyunsaturated fatty acid impairment of early host resistance against Listeria monocytogenes infection is independent of neutrophil infiltration and function 2005 ·Cellular Immunology ·Kevin L. Fritsche, Robert Irons, (unknown), Julie Janes, Zhiqiang Zheng, Charles R. Brown	12
19	Raising perceptual awareness in work with women and girls 1986 ·Medical Entomology and Zoology ·Karen Evans, (unknown), Julie Janes	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact